Myrtle Clinical|myrtleclinical.org
Operations · The Myrtle Magazine

The most expensive color in clinical trials

A green status is not the same as a healthy trial. The detail you actually needed usually sits one layer below the summary.

By Hadas Nachmanson, founder of Myrtle Clinical · June 2026

If you're a biotech founder running your trial through a CRO, this one is for you.

Status reports are built to roll up, to summarize, to reassure. That is not a flaw, it is their purpose. But it means the operational truth, the detail you actually needed, often sits one layer below what you are shown.

I have reviewed plenty of trials where the dashboard was green and the reality was amber. Not because anyone was hiding anything, but because the reporting smoothed the edges. Issues were aggregated. Aging was averaged. "Under control" quietly absorbed "open for three months."

The trial sponsor was not misled. They were not fully informed, by a system working exactly as designed.

Independent oversight is not about distrust. It is about cross checking what is reported against what is actually in the data, at the sites, and in the numbers.

The most expensive color in clinical trials is a green status that nobody verified.

Read below the summary. That is where the trial actually lives.

By Hadas Nachmanson, Founder of Myrtle Clinical · LinkedIn

Running a trial through a CRO?

Myrtle Clinical is the independent clinical operations representative on the sponsor's side only: overseeing and managing the CRO and vendors so your trial stays on schedule, on budget, and inspection-ready.

Meet Myrtle Clinical →